Calling all patients and caregivers with experience with Votrient (also known as pazopanib).
Some of you know that Canada has a brand new drug review process called pCODR (pan-Canadian Oncology Drug Review). This process will evaluate new cancer drugs and make recommendations for funding to all provinces except the province of Quebec (which has its own process).
The pCODR process includes two key places where patient advocacy groups can provide input. Kidney Cancer Canada believes that Votrient (pazopanib) will be one of the first new drugs to go through this new process. And we’re keen to provide a valuable patient evidence submission based upon Canadian patient experiences.
To do that, we need your help. Our goal is to reach as many patients and caregivers who have had personal experience with Votrient as possible. So, whether you took Votrient for 2 weeks or 2 years, we need to include your fair and honest input.
We have developed a series of questions based upon past experiences with patient evidence submissions and the types of questions we usually need to answer. The survey questions are posted on our website here. Please answer as many questions as you are able and email your responses to firstname.lastname@example.org
Some patients known to be taking Votrient will be receiving a phone call. Please answer the questions just once, by phone or email. Thank you in advance.
If you have questions, please call us at 1-866-598-7166 or post a comment or question here.